infliximab

Infliximab is a monoclonal antibody, a human-mouse chimeric monoclonal antibody that inhibits TNF-α and prevents TNF-α from interacting with TNFR1 and TNFR2. Infliximab can be used to treat Crohn's disease and rheumatoid arthritis.

LEESGGGLVQPGGSMK acetate is a proteolysis peptide found in Infliximab, a chimeric monoclonal IgG1 antibody. It serves as a component of Infliximab and can be employed for the quantitative analysis of this antibody. Infliximab is specifically designed to bind to TNF-α[1].

DSTYSLSSTLTLSK, a human peptide, facilitates the quantitative detection of Infliximab (Avakine), a chimeric monoclonal IgG1 antibody. Infliximab specifically targets and binds to TNF-α.

DSTYSLSSTLTLSK acetate is a human generic peptide that can be used for the quantitative detection of infliximab.

LEESGGGLVQPGGSMK, a proteolysis peptide, is a component of Infliximab, a chimeric monoclonal IgG1 antibody that selectively binds to TNF-α. It is used for the quantitative assessment of Infliximab.

LEESGGGLVQPGGSMK TFA, a proteolysis peptide component of Infliximab, serves for the quantitative analysis of the latter. Infliximab is a chimeric monoclonal IgG1 antibody, binding specifically to TNF-α [1].

DSTYSLSSTLTLSK TFA, a generic human peptide, facilitates the quantitative detection of Infliximab (Avakine), a chimeric monoclonal IgG1 antibody targeting TNF-α, as indicated in study [1].